{
    "symbol": "IQV",
    "quarter": 1,
    "year": 2022,
    "date": "2022-04-27 14:28:04",
    "content": " We're seeing clinical trials start up 7% in the first quarter compared to last year, with a 14% increase in oncology trial starts, which is a therapeutic area, as you well know, that's predominantly sponsored by EBP. First quarter revenue of $3,568 million grew 4.7% on a reported basis and 6.8% at constant currency. Technology and Analytic Solutions revenue for the first quarter was $1,439 million, which was up 6.8% reported and 9.8% at constant currency. R&D Solutions first quarter revenue of $1,934 million was up 3.5% at actual FX rates and 4.7% at constant currency. For the full year, we now expect revenue to be between $14,450 million and $14,750 million, which represents year-over-year growth of 6.9 to 9%, at constant currency and 4.2% to 6.3% reported, both compared to 2021. So for the second quarter revenue is expected to be between $3,470 million and $3,520 million representing growth of 4.6% to 6% on a constant currency basis and 0.9% to 2.4% on a reported basis. Our R&DS bookings for business recorded its largest ever quarter of service bookings, contracted backlog exceeded $25 billion for the first time rising over 9% year-over-year with over $7 billion expected to convert to revenue over the next 12 months. Your line is open, please ask your question. So again, I mean, in TAS I can tell you the, what's built in our forecast and reflected in our guidance is due to constant currency organic growth, excluding COVID related work will be high single digits, so very consistent again with the first quarter. Your line is open, please ask your question. Your line is open, please ask your question. Your line is open, please ask your question. Your line is open, please ask your question."
}